To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.
Summary
What This Bill Does
The bill creates credit for pharmaceutical and medical device production activities in distressed zones Subpart D of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by adding at the end and creates 45BB. Distressed zone pharmaceutical and medical device production credit. It relies on definition changes, tax credits, compliance mandates, and product standards. The main policy areas are Healthcare Consumers, Finance, and Healthcare.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could face reduced risk.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill would take on compliance duties, and Businesses and employers affected by the bill would take on compliance duties.
Key Provisions
- Creates credit for pharmaceutical and medical device production activities in distressed zones Subpart D of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by adding at the end...
- Creates 45BB. Distressed zone pharmaceutical and medical device production credit.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates credit for pharmaceutical and medical device production activities in distressed zones Subpart D of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by adding at the end and creates 45BB. Distressed zone pharmaceutical and medical device production credit.
Key Policy Areas
Healthcare Consumers, Finance, Healthcare
Primary Purpose
The bill creates credit for pharmaceutical and medical device production activities in distressed zones Subpart D of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by adding at the end and creates 45BB. Distressed zone pharmaceutical and medical device production credit.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
- Businesses and employers affected by the bill
Sponsors
Legislative Progress
IntroducedMr. Carter of Georgia (for himself, Mr. Soto, Mrs. Miller …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology